Work

Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model

Year: 2014

Type: article

Abstract: Meeting abstracts Coxsackievirus A21 (CAVATAK™) is a bio-selected oncolytic immunotherapy virus. Following intratumoral (i.t) injection, CAVATAK selectively infects ICAM-1-expressing tumor cells, resulting in tumor cell lysis and a systemic immune-mediated anti-tumor response. A Phase II trial of

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-2-s3-p125

Authors: Darren Shafren, Min Quah, Yvonne Wong, Robert HI Andtbacka, Howard L Kaufman, Gough G Au

Institutions: Viralytics Limited (Australia), University of Newcastle Australia, Huntsman Cancer Institute, Rutgers Cancer Institute

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490